Ken Griffin Galapagos Nv Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$24.2 - $30.67 $174,240 - $220,824	7,200 Added 97.3%	14,600 $420,000
Q2 2024 Aug 14, 2024	BUY	$24.78 - $32.48 $14,868 - $19,487	600 Added 8.82%	7,400 $183,000
Q1 2024 May 15, 2024	SELL	$32.2 - $42.44 $51,520 - $67,904	-1,600 Reduced 19.05%	6,800 $218,000
Q4 2023 Feb 14, 2024	BUY	$31.87 - $40.71 $108,358 - $138,414	3,400 Added 68.0%	8,400 $341,000
Q3 2023 Nov 14, 2023	BUY	$34.17 - $42.98 $68,340 - $85,960	2,000 Added 66.67%	5,000 $172,000
Q2 2023 Aug 14, 2023	BUY	$37.4 - $44.52 $7,480 - $8,904	200 Added 7.14%	3,000 $121,000
Q1 2023 May 15, 2023	SELL	$36.5 - $48.0 $1.85 Million - $2.44 Million	-50,800 Reduced 94.78%	2,800 $108,000
Q4 2022 Feb 14, 2023	BUY	$37.44 - $46.51 $1.26 Million - $1.56 Million	33,600 Added 168.0%	53,600 $2.38 Million
Q3 2022 Nov 14, 2022	SELL	$42.27 - $57.6 $731,271 - $996,480	-17,300 Reduced 46.38%	20,000 $853,000

12.3M

69.1K

42.7K

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.76B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.